Table 3.
Group1 (n = 54) | Group2 (n = 85) | χ2 | P value | |
---|---|---|---|---|
ORR | 18/54 (33.30%) | 21/85 (24.70%) | 1.110 | 0.292 |
DCR | 47/54 (87.00%) | 63/85 (74.10%) | 0.089 | 0.765 |
Group1, lenvatinib plus sintilimab treatment group; Group2, lenvatinib monotherapy group.
Objective response rate (ORR); Disease Control Rate (DCR).